NEW YORK, Feb. 9, 2015 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Puma Biotechnology, Inc. ("Puma" or the "Company") (NYSE: PBYI).
The investigation focuses on whether the Company and its executives violated federal securities laws by issuance of certain statements regarding a New Drug Application ("NDA") submission.
On December 2, 2014, Puma announced that an NDA would be filed for neratinib (PB272), a breast cancer drug candidate, in the first quarter of 2016 rather than the first half of 2015 as previously stated.
Following news of the delay in filing, Puma shares declined by $27.33 per share, more than 12%, closing on December 3, 2014 at $197.67 per share.
Request more information now by clicking here: www.faruqilaw.com/PBYI. There is no cost or obligation to you.
Take Action
If you invested in Puma stock or options through December 2, 2014 and would like to discuss your legal rights, visit www.faruqilaw.com/PBYI. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected]. Faruqi & Faruqi, LLP also encourages anyone with information regarding Puma's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
[email protected]
Telephone: (877) 247-4292 or (212) 983-9330
Logo - http://photos.prnewswire.com/prnh/20120119/MM38856LOGO
SOURCE Faruqi & Faruqi, LLP
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article